4a39 | Huvepharma EOOD | Endo-1,4-beta-xylanase (EC 3.2.1.8)Endo-1,4-beta-glucanase (EC 3.2.1.4) Xyloglucan-specific-endo-beta-1,4-glucanase (EC 3.2.1.151) | Additive compositionPreparation of endo-1,4-beta-xylanase, endo-1,4-beta-glucanase and xyloglucan-specific-endo-beta-1,4-glucanase produced with Trichoderma citrinoviride DSM 33578 having a minimum activity of:Endo-1,4-beta-xylanase: 15000 EPU/g,Endo-1, 4-beta-glucanase: 1000 CU/g,Xyloglucan-specific endo- beta-1,4-glucanase: 1000 XGU/g.Granulated or liquid form.Characterisation of the active substanceEndo-1,4-beta-xylanase (EC 3.2.1.8), endo-1,4-beta-glucanase (EC 3.2.1.4) and xyloglucan-specific-endo-beta-1,4-glucanase (EC 3.2.1.151) produced with Trichoderma citrinoviride DSM 33578Analytical methodFor the determination of endo-1,4-beta-xylanase activity in the feed additive, premixtures and compound feed:- colorimetric method measuring water soluble dye released by action of endo-1,4-beta-xylanase from azurine cross-linked wheat arabinoxylan substrate.
For the determination of endo-1,4-beta-glucanase activity in the feed additive, premixtures and compound feed:- colorimetric method based on the quantification of water soluble dyed fragments (azurine) produced by the action of endo-1,4-beta-glucanase on azurine-crosslinked cellulose.
For the determination of xyloglucan-specific-endo-beta-1,4-glucanase activity in the feed additive, premixtures and compound feed:- colorimetric method based on the quantification of soluble dyed labelled fragments produced by the action of xyloglucan-specific-endo-beta-1,4-glucanase on xyloglucan substrate.
| Sows of all Suidae species | - | Endo-1,4-beta-xylanase 1500 EPUEndo-1, 4-beta- glucanase 100 CUXyloglucan- specific endo- beta-1,4-glucanase 100 XGU | - | 1.In the directions for use of the additive and premixtures, the storage conditions and stability to heat treatment shall be indicated.2.For users of the additive and premixtures, feed business operators shall establish operational procedures and organisational measures to address the potential risks resulting from their use. Where those risks cannot be eliminated by such procedures and measures, the additive and premixtures shall be used with personal breathing and skin protective equipment. | 23 September 2034 |